Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

医学 内科学 多发性骨髓瘤 生活质量(医疗保健) 耐火材料(行星科学) 临床试验 癌症 嵌合抗原受体 肿瘤科 免疫疗法 物理 护理部 天体生物学
作者
Thomas G Martin,Yi Lin,Mounzer Agha,Adam D. Cohen,Myo Htut,A. Keith Stewart,Parameswaran Hari,Jesús G. Berdeja,Saad Z. Usmani,Tzu‐Min Yeh,Yunsi Olyslager,Jenna D. Goldberg,Jordan Mark Schecter,Deepu Madduri,Carolyn Chang Jackson,William M Deraedt,Katharine S. Gries,John M. Fastenau,Jeremiah Trudeau,Muhammad Akram
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:9 (12): e897-e905 被引量:47
标识
DOI:10.1016/s2352-3026(22)00284-8
摘要

CARTITUDE-1 is a phase 1b-2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma. Primary efficacy outcomes have previously been reported. Here, we report health-related quality of life (HRQOL) secondary outcomes evaluated using patient-reported outcomes.This single-arm, open-label, phwase 1b-2 study was done at 16 centres in the USA. Patients were aged 18 years or older with diagnosis of multiple myeloma and Eastern Cooperative Oncology Group performance status of 1 or less with three or more previous lines of therapy, or were double refractory to a proteasome inhibitor and immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody. A single cilta-cel infusion (target dose 0·75 × 106 CAR+ T cells per kg) was administered 5-7 days after lymphodepletion. Patient-reported outcomes were assessed using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire core 30-item, pre-specified items from the EORTC myeloma module, and EuroQol five-dimensional descriptive system questionnaire. Clinically meaningful changes in patient-reported outcomes were defined by anchor-based minimally important differences. This trial is registered with ClinicalTrials.gov, NCT03548207. This trial is completed but feeding into a long-term follow-up study.Between July 16, 2018, and Oct 7, 2019, 78 patients were enrolled and underwent apheresis in phase 2 of the study. 68 patients were treated (43 [63%] male, 49 [72%] White), and their patient-reported outcomes assessed (median follow-up 16·9 months, IQR 15·7-17·5). After infusion, a transient decline was observed, followed by improvements in global health status (mean change from baseline to day 464 +8·0 points, SD 20·9), physical (+4·6 points, 21·1), and emotional functional scales (+1·9 points, 23·7) over time, and declines for symptom-based scores (-14·1 pain, SD 31·5 and -15·4 fatigue; SD 29·5), indicating improved patient HRQOL following treatment with cilta-cel.These durable HRQOL improvements are consistent with clinical findings, in which a single cilta-cel infusion led to substantial and durable responses in heavily pre-treated patients with relapsed or refractory multiple myeloma. These results support the use of cilta-cel in patients with relapsed or refractory multiple myeloma.Janssen Research & Development and Legend Biotech USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
momo完成签到,获得积分10
1秒前
求知小生完成签到 ,获得积分10
3秒前
Ava完成签到,获得积分10
4秒前
5秒前
冷傲的婷冉完成签到,获得积分10
7秒前
Ayun完成签到,获得积分10
7秒前
8秒前
Ayun发布了新的文献求助10
11秒前
爱听歌的香萱完成签到,获得积分10
11秒前
翰飞寰宇完成签到 ,获得积分10
13秒前
wangji_2017发布了新的文献求助10
14秒前
甘sir完成签到 ,获得积分0
17秒前
18秒前
何一非完成签到,获得积分10
22秒前
阳阳完成签到 ,获得积分10
24秒前
蓝梦诗音完成签到 ,获得积分10
24秒前
腼腆的山兰完成签到 ,获得积分10
28秒前
laurina完成签到 ,获得积分10
29秒前
眼睛大淇完成签到,获得积分10
35秒前
boom完成签到 ,获得积分10
37秒前
偶尔向上idiot完成签到 ,获得积分10
37秒前
45秒前
king完成签到 ,获得积分10
47秒前
48秒前
153266916完成签到 ,获得积分10
52秒前
文文发布了新的文献求助10
54秒前
韩梅完成签到 ,获得积分10
58秒前
活力尔柳完成签到 ,获得积分10
1分钟前
1分钟前
起名困难户完成签到,获得积分10
1分钟前
u雨发布了新的文献求助10
1分钟前
小周完成签到 ,获得积分10
1分钟前
齐天小圣完成签到 ,获得积分10
1分钟前
u雨完成签到,获得积分10
1分钟前
困困困完成签到,获得积分10
1分钟前
忧伤的白秋完成签到,获得积分10
1分钟前
勤劳的乐蕊完成签到,获得积分10
1分钟前
噜噜晓完成签到 ,获得积分10
1分钟前
呆橘完成签到 ,获得积分10
1分钟前
踏实谷蓝完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012